With a population of 1.4 billion and a rapidly aging population, the cost of pharmaceuticals in China is significant and demands a large share of national health care spending.
China's current political efforts in the healthcare sector, and particularly in the pharmaceutical segment, are aimed at making universal healthcare efficient. The demand for medicines has grown considerably and the healthcare system as a whole is increasingly under pressure. Providing access to medicines for the population is a key priority for the Chinese government. In order to make this universal health care affordable with the available financial resources, measures have been taken, particularly with regard to the selection and distribution of medicines and the payment obligations of public insurance companies. Generic drugs account for over 80% of all drugs sold in China and procurement instruments such as tenders are controlled by local government systems.
Bioqom has developed instruments to make access to the procurement system in China transparent and effective. These relate both to the exchange with relevant institutions and to the implementation of the tendering process. In particular, urgently needed groups of drugs find long-term, secure sales in China through efficient import mechanisms.